ECSP22001370A - Inhibidores de prmt5 - Google Patents

Inhibidores de prmt5

Info

Publication number
ECSP22001370A
ECSP22001370A ECSENADI20221370A ECDI202201370A ECSP22001370A EC SP22001370 A ECSP22001370 A EC SP22001370A EC SENADI20221370 A ECSENADI20221370 A EC SENADI20221370A EC DI202201370 A ECDI202201370 A EC DI202201370A EC SP22001370 A ECSP22001370 A EC SP22001370A
Authority
EC
Ecuador
Prior art keywords
overexpression
disorders
prmt5
prmt5 inhibitors
relates
Prior art date
Application number
ECSENADI20221370A
Other languages
English (en)
Inventor
Rajender Kumar Kamboj
Chaitanya Kulkarni
Dipak Lagad
Mahadeo Tryambake
Chetan Pawar
Milind Sindkhedkar
Ganesh Gudade
Prathap Nair
Venkata Palle
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of ECSP22001370A publication Critical patent/ECSP22001370A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a análogos de nucleósidos sustituidos de fórmula (I), a sales farmacéuticamente aceptables de los mismos y a composiciones farmacéuticas para tratar enfermedades, trastornos o afecciones asociados con la sobreexpresión de la enzima PRMT5. La invención también se refiere a métodos para tratar enfermedades, trastornos o afecciones asociados con la sobreexpresión de la enzima PRMT5.
ECSENADI20221370A 2019-06-10 2022-01-07 Inhibidores de prmt5 ECSP22001370A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921022972 2019-06-10
IN201921022971 2019-06-10

Publications (1)

Publication Number Publication Date
ECSP22001370A true ECSP22001370A (es) 2022-02-25

Family

ID=71670318

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20221370A ECSP22001370A (es) 2019-06-10 2022-01-07 Inhibidores de prmt5

Country Status (30)

Country Link
US (1) US12391695B2 (es)
EP (1) EP3980417B1 (es)
JP (1) JP7686579B2 (es)
KR (1) KR20220019781A (es)
CN (1) CN114026094B (es)
AU (1) AU2020293021B2 (es)
BR (1) BR112021024999A2 (es)
CA (1) CA3141748A1 (es)
CL (1) CL2021003292A1 (es)
CO (1) CO2022000061A2 (es)
CR (1) CR20220010A (es)
CY (1) CY1126537T1 (es)
DK (1) DK3980417T3 (es)
EC (1) ECSP22001370A (es)
ES (1) ES2967457T3 (es)
FI (1) FI3980417T3 (es)
HR (1) HRP20231673T1 (es)
HU (1) HUE064493T2 (es)
IL (1) IL288401A (es)
LT (1) LT3980417T (es)
MX (1) MX2021015262A (es)
PE (1) PE20230245A1 (es)
PH (1) PH12021553082A1 (es)
PL (1) PL3980417T3 (es)
PT (1) PT3980417T (es)
RS (1) RS64972B1 (es)
SI (1) SI3980417T1 (es)
SM (1) SMT202400014T1 (es)
WO (1) WO2020250123A1 (es)
ZA (1) ZA202109573B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4069698A1 (en) * 2019-12-03 2022-10-12 Lupin Limited Substituted nucleoside analogs as prmt5 inhibitors
WO2022271540A1 (en) * 2021-06-21 2022-12-29 Mayo Foundation For Medical Education And Research Inhibitors of dot1l
US20240368153A1 (en) * 2021-07-02 2024-11-07 Mirati Therapeutics, Inc. Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
CN121925419A (zh) * 2023-09-06 2026-04-24 赛诺哈勃药业(成都)有限公司 一种吡啶-2(1h)-酮类prmt5-mta抑制剂、其药物组合物及其应用
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
FR3161349B1 (fr) * 2024-04-17 2026-04-10 Univ Sorbonne Nouveaux inhibiteurs des transporteurs de cations organiques pour le traitement des troubles de l’humeur
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57163383A (en) * 1980-12-12 1982-10-07 Toyo Jozo Co Ltd Neplanocin a derivative
US4975434A (en) * 1986-05-27 1990-12-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antiviral and anticancer cyclopentenyl cytosine
ATE336492T1 (de) * 2000-01-14 2006-09-15 Us Gov Health & Human Serv Methonocarbacycloalkylanaloga von nucleosiden
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
TWI412322B (zh) 2005-12-30 2013-10-21 杜邦股份有限公司 控制無脊椎害蟲之異唑啉
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
WO2009074487A1 (en) 2007-12-11 2009-06-18 F. Hoffmann-La Roche Ag Inhibitors of stearoyl-coa desaturase
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
AR074024A1 (es) 2008-11-14 2010-12-15 Merial Ltd Compuesto de arilazol-2-il-cianoetilamino enantiomericamente enriquecidos, composicion plaguicida y su uso para prevenir la infeccion parasitaria
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
WO2011079236A1 (en) 2009-12-22 2011-06-30 The Ohio State University Research Foundation Compositions and methods for cancer detection and treatment
JP5744021B2 (ja) 2010-06-30 2015-07-01 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
WO2012037108A1 (en) 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
CN104662018B (zh) * 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
US10118918B2 (en) 2012-12-21 2018-11-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
JP2016505002A (ja) 2012-12-21 2016-02-18 エピザイム,インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するprmt5阻害剤およびその使用
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
US9908887B2 (en) 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9365555B2 (en) 2012-12-21 2016-06-14 Epizyme, Inc. PRMT5 inhibitors and uses thereof
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
JP6510485B2 (ja) 2013-03-15 2019-05-08 オハイオ・ステイト・イノベーション・ファウンデーション Prmt5インヒビターおよびそれらの使用方法
MX380928B (es) 2013-10-10 2025-03-12 Araxes Pharma Llc Inhibidores de kras g12c.
EP3160466A4 (en) 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
DK3160958T3 (da) 2014-06-25 2021-04-12 Glaxosmithkline Ip Dev Ltd Krystallinske salte af (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidin-4-carboxamid
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
AU2015301196A1 (en) 2014-08-04 2017-01-12 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
WO2016038550A1 (en) 2014-09-11 2016-03-17 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
US20180271891A1 (en) 2015-03-11 2018-09-27 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI730980B (zh) * 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
TW201722957A (zh) 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
WO2017100716A1 (en) 2015-12-11 2017-06-15 Eaton Corporation Autonomous dock
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
WO2018065365A1 (en) * 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
WO2018085818A1 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152548A1 (en) * 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018167800A1 (en) 2017-03-13 2018-09-20 Impetis Biosciences Limited Fused bicyclic compounds, compositions and applications thereof
CR20200263A (es) * 2017-12-13 2020-07-26 Lupin Ltd Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
EP4069698A1 (en) * 2019-12-03 2022-10-12 Lupin Limited Substituted nucleoside analogs as prmt5 inhibitors

Also Published As

Publication number Publication date
AU2020293021A1 (en) 2021-12-23
PE20230245A1 (es) 2023-02-07
RS64972B1 (sr) 2024-01-31
ES2967457T3 (es) 2024-04-30
EP3980417B1 (en) 2023-09-27
CY1126537T1 (el) 2026-02-25
CR20220010A (es) 2022-05-13
PH12021553082A1 (en) 2023-09-11
EP3980417A1 (en) 2022-04-13
AU2020293021B2 (en) 2025-10-02
BR112021024999A2 (pt) 2022-01-25
IL288401A (en) 2022-01-01
HUE064493T2 (hu) 2024-03-28
PT3980417T (pt) 2023-12-28
CN114026094B (zh) 2024-06-25
CL2021003292A1 (es) 2022-08-19
CA3141748A1 (en) 2020-12-17
WO2020250123A1 (en) 2020-12-17
HRP20231673T1 (hr) 2024-03-15
US12391695B2 (en) 2025-08-19
SI3980417T1 (sl) 2024-02-29
DK3980417T3 (en) 2023-12-18
MX2021015262A (es) 2022-04-06
KR20220019781A (ko) 2022-02-17
LT3980417T (lt) 2023-12-27
FI3980417T3 (fi) 2023-12-28
JP2022536337A (ja) 2022-08-15
JP7686579B2 (ja) 2025-06-02
SMT202400014T1 (it) 2024-03-13
CO2022000061A2 (es) 2022-04-08
US20220315589A1 (en) 2022-10-06
PL3980417T3 (pl) 2024-03-18
CN114026094A (zh) 2022-02-08
ZA202109573B (en) 2022-11-30

Similar Documents

Publication Publication Date Title
CO2022000061A2 (es) Inhibidores de prmt5
CL2020001576A1 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5.
MX2023007192A (es) Inhibidores de prmt5.
BR112021022457A2 (pt) Inibidores de fgfr e métodos de uso dos mesmos
CY1126110T1 (el) Παραγωγα βενζοϋδροξαμικου οξεος ως εκλεκτικοι αναστολε1σ του hdac6
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
BR112021018664A2 (pt) Inibidores de proteína tirosina fosfatase
EA202193015A1 (ru) Ингибиторы cdk
BR112021020285A2 (pt) Métodos e composições para degradação de proteína alvejada
MX2021011606A (es) Compuestos dirigidos a prmt5.
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
NO20076093L (no) Substituerte amidderivater som proteinkinaseinhibitorer
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
MX2022006735A (es) Análogos de nucleósidos sustituidos como inhibidores de la prmt5.
MX394700B (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk
UY38233A (es) Agentes inhibidores para la tirosina cinasa de bruton
MX2022002443A (es) Compuestos inhibidores de perk.